Windtree Therapeutics Operating Income Over Time
| WINT Stock | USD 0.50 0.01 1.96% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Windtree Therapeutics Performance and Windtree Therapeutics Correlation. Windtree |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Windtree Therapeutics. If investors know Windtree will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Windtree Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (19.03) | Quarterly Revenue Growth (1.00) | Return On Assets (0.45) | Return On Equity (1.51) |
The market value of Windtree Therapeutics is measured differently than its book value, which is the value of Windtree that is recorded on the company's balance sheet. Investors also form their own opinion of Windtree Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Windtree Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Windtree Therapeutics' market value can be influenced by many factors that don't directly affect Windtree Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Windtree Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Windtree Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Windtree Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Operating Income Analysis
Compare Windtree Therapeutics and related stocks such as Neurobo Pharmaceuticals, Palisade Bio, and Lixte Biotechnology Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NRBO | (266 K) | (266 K) | (266 K) | (266 K) | (266 K) | (8.1 M) | (14.7 M) | (33.1 M) | (22.8 M) | (20.2 M) | (29.7 M) | (15.3 M) | (19.6 M) | (15.9 M) | (16.7 M) |
| PALI | (3.2 M) | (13 M) | (10.2 M) | (12.5 M) | (17.4 M) | (19.2 M) | (20.6 M) | (13.3 M) | (8.3 M) | (8.6 M) | (9.3 M) | (41.9 M) | (15.7 M) | (13.1 M) | (13.7 M) |
| LIXT | (32.9 K) | (1.9 M) | (2.1 M) | (1.4 M) | (2.4 M) | (2.6 M) | (2.1 M) | (1.8 M) | (2.1 M) | (2.5 M) | (3.3 M) | (6.7 M) | (6.3 M) | (5.1 M) | (4.8 M) |
| ATXI | (4.8 M) | (4.8 M) | (4.8 M) | (4.8 M) | (4.8 M) | (4.8 M) | (2.4 M) | (11.4 M) | (21.8 M) | (26.3 M) | (5.2 M) | (3.7 M) | (8 M) | (14.5 M) | (15.3 M) |
Windtree Therapeutics and related stocks such as Neurobo Pharmaceuticals, Palisade Bio, and Lixte Biotechnology Operating Income description
Operating Income is the amount of profit realized from Windtree Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Windtree Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Windtree Therapeutics | WINT |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Pennsylvania; U.S.A |
| Exchange | NASDAQ Exchange |
USD 0.5
Additional Tools for Windtree Stock Analysis
When running Windtree Therapeutics' price analysis, check to measure Windtree Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Windtree Therapeutics is operating at the current time. Most of Windtree Therapeutics' value examination focuses on studying past and present price action to predict the probability of Windtree Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Windtree Therapeutics' price. Additionally, you may evaluate how the addition of Windtree Therapeutics to your portfolios can decrease your overall portfolio volatility.